A practical reference on shelf life: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-26 and is reviewed periodically as new material appears.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Coordination compound rather than a simple salt |
| Peptide sequence | Glycyl-L-histidyl-L-lysine | Abbreviated GHK in most literature |
| Molecular formula | C14H22N6O4Cu | Reported for the 1:1 complex |
| Principal binding site | Histidine imidazole nitrogen | Backbone amides contribute additional coordination |
| Common synonym | Copper tripeptide-1 | Used in ingredient and product labelling |
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
=== Systemic factors === Inflammation Diabetes – Individuals with diabetes demonstrate reduced capability in the healing of acute wounds. Additionally, diabetic individuals are susceptible to developing chronic diabetic foot ulcers, a serious complication of diabetes which affects 15% of people with diabetes and accounts for 84% of all diabetes-related lower leg amputations. The impaired healing abilities of diabetics with diabetic foot ulcers and/or acute wounds involves multiple pathophysiological mechanisms. This impaired healing involves hypoxia, fibroblast and epidermal cell dysfunction, impaired angiogenesis and neovascularization, high levels of metalloproteases, damage from reactive oxygen species and AGEs (advanced glycation end-products), decreased host immune resistance, and neuropathy. Nutrients – Malnutrition or nutritional deficiencies have a recognizable impact on wound healing post trauma or surgical intervention. Nutrients including proteins, carbohydrates, arginine, glutamine, polyunsaturated fatty acids, vitamin A, vitamin C, vitamin E, magnesium, copper, zinc and iron all play significant roles in wound healing. Fats and carbohydrates provide the majority of energy required for wound healing. Glucose is the most prominent source of fuel and it is used to create cellular ATP, providing energy for angiogenesis and the deposition of new tissues. As the nutritional needs of each patient and their associated wound are complex, it is suggested that tailored nutritional support would benefit both acute and chronic wound healing.
=== Filler injections === Filler injections of collagen can be used to raise atrophic scars to the level of surrounding skin. Risks vary based upon the filler used, and can include further disfigurement and allergic reaction.
=== Oxygen compounds === Three americium oxides are known, with the oxidation states +2 (AmO), +3 (Am2O3) and +4 (AmO2). Americium(II) oxide was prepared in minute amounts and has not been characterized in detail. Americium(III) oxide is a red-brown solid with a melting point of 2205 °C. Americium(IV) oxide is the main form of solid americium which is used in nearly all its applications. As most other actinide dioxides, it is a black solid with a cubic (fluorite) crystal structure. The oxalate of americium(III), vacuum dried at room temperature, has the chemical formula Am2(C2O4)3·7H2O. Upon heating in vacuum, it loses water at 240 °C and starts decomposing into AmO2 at 300 °C, the decomposition completes at about 470 °C. The initial oxalate dissolves in nitric acid with the maximum solubility of 0.25 g/L.
Sources: en.wikipedia.org
Early undiagnosed rheumatic diseases such as preclinical rheumatoid arthritis, early stages of inflammatory spondyloarthritis, polymyalgia rheumatica, myofascial pain syndromes and hypermobility syndrome. Neurological diseases that can have important pain and fatigue components include multiple sclerosis, Parkinson's disease and peripheral neuropathy. Other medical illnesses that should be ruled out are endocrine disease or metabolic disorder (hypothyroidism, hyperparathyroidism, acromegaly, vitamin D deficiency), gastro-intestinal disease (celiac and non-celiac gluten sensitivity), infectious diseases (Lyme disease, hepatitis C and immunodeficiency disease) and the early stages of a malignancy such as multiple myeloma, metastatic cancer and leukemia/lymphoma. Other systemic, inflammatory, endocrine, rheumatic, infectious, and neurologic disorders may cause fibromyalgia-like symptoms, such as systemic lupus erythematosus, Sjögren's disease, ankylosing spondylitis, Ehlers-Danlos syndromes, psoriatic-related polyenthesitis, a nerve compression syndrome (such as carpal tunnel syndrome), and myasthenia gravis. Several medications can evoke pain (statins, aromatase inhibitors, bisphosphonates, and opioids).
In continuum mechanics, viscosity is a property of a fluid that quantifies the resistance force acting on fluids when there is relative motion between fluid parcels. This resistance force is caused by the stress in fluid parcels, which ideally is directly proportional to the strain rate (the time derivative of strain) that arises when fluid parcels are in relative motion, and the relative speed between the boundary between adjacent fluid parcels is zero. In liquids, viscosity arises from cohesive molecular forces, while in gases it results from molecular collisions. Except for the case of superfluidity, there is no fluid with zero viscosity, and thus all fluid flows involve viscous effects to some degree. For liquids, it corresponds to the informal concept of thickness; for example, syrup has a higher viscosity than water. Viscosity is defined scientifically as a force multiplied by a time divided by an area. Thus its SI units are newton-seconds per metre squared, or pascal-seconds. For instance, when a viscous fluid is forced through a tube, it flows more quickly near the tube's center line than near its walls. Some stress (such as a pressure difference between the two ends of the tube) is needed to sustain the flow. This is because a force is required to overcome the friction between the layers of the fluid which are in relative motion. For a tube with a constant rate of flow, the strength of the compensating force is proportional to the fluid's viscosity. In general, viscosity depends on a fluid's state, such as its temperature, pressure, and rate of deformation.
Martinez (1977), 8th Virginia secretary of transportation and deputy administrator of the United States Maritime Administration David Paterson (1977), first African-American governor of New York Karl Dean (1978), mayor of Nashville Christopher Dell (1978), career diplomat, former US ambassador to Zimbabwe, Angola, and Kosovo Martin J. Dunn (1979), former mayor of Holyoke, Massachusetts and member of the Massachusetts Senate Jim McGreevey (1978), 53rd governor of New Jersey Andres Alonso (1979), former CEO of Baltimore City Public Schools Timothy Horrigan (1979), member of the New Hampshire House of Representatives Randal Quarles (1981), 15th under secretary of the treasury for domestic finance, chair of the Financial Stability Board and vice chairman of the Federal Reserve Andrew C. McCarthy (1981), assistant U.S. attorney and columnist for National Review Charles J. O'Byrne (1981), secretary to the governor of New York Michael Waldman (1982), speechwriter for president Clinton; president of the Brennan Center for Justice John Solecki (1982), U.S. official for the United Nations high commissioner for Refugees, kidnapped in Pakistan by the Balochistan Liberation United Front in 2009 Barack Obama (1983), 44th president of the United States and first African-American to hold the office; former senator from Illinois; winner of the 2009 Nobel Peace Prize Victor Cha (1983), foreign policy expert; President Bush's top advisor on North Korean affairs Jay Lefkowitz (1984), George W.
Sources: en.wikipedia.org
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.
The chain occurs in human plasma, saliva, and urine. Measured amounts are reported to fall with age. Copper binding by the sequence is treated as part of normal metal handling in tissue.
The bound copper(II) centre contributes to redox behaviour and to stability under physiological conditions. Free copper ions can participate in reactions that generate reactive species, while chelated metal is generally more controlled. The chain may also serve as a carrier for copper in experimental systems.
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.